China's biopharmaceutical industry drives social development
Release time:
2016-04-16
The world's richest man, Bill Gates, once predicted that the next richest man in the world who will surpass him will definitely come from the field of genetics.
The biopharmaceutical industry is composed of the biotechnology industry and the pharmaceutical industry. Modern biotechnology represented by genetic engineering, cell engineering, enzyme engineering, and fermentation engineering has developed rapidly in recent years. At present, biological drugs that have been developed and entered the clinical application stage by humans can be divided into three categories according to their different uses, namely genetic engineering drugs, biological vaccines, and biological diagnostic reagents. These biopharmaceutical products are beginning to increasingly affect and change people's production and lifestyle.
The "2016-2021 China Biopharmaceutical Industry Market Demand Forecast and Investment Strategy Planning Analysis Report" by the Forward-looking Industry Research Institute shows that since the 1990s, biopharmaceuticals have maintained a rapid annual growth rate of 15%-30%, far higher than the global pharmaceutical industry's average growth rate of less than 10%, and have entered the initial stage of large-scale industrialization.
In recent years, my country has vigorously supported the development of the biopharmaceutical industry. Through government guidance and private investment, the biopharmaceutical industry has shown a trend of concentrated development, and my country has formed a relatively complete industrial cluster and biopharmaceutical industry chain. Industry insiders believe that the reasons for the rapid development of my country's biopharmaceutical industry are: first, the main deployment of enterprises is concentrated in areas where colleges and universities are concentrated or in their surrounding areas, where most of them are areas with dense biotechnology and talents; second, they are concentrated in provinces and cities with relatively developed economies and intensive capital, and have formed a certain scale, such as Guangdong, Shandong, Jiangsu and Zhejiang. The common feature of these places is that the local biopharmaceutical industry clusters have their own relatively complete industrial chains, which include a large number of internal institutions such as biological companies, technology transfer centers, research centers, investment institutions, banks, and services, and have initially formed a relatively good innovation and entrepreneurship environment consisting of six major modules: research and development, pharmaceutical production, education and training, incubation and innovation, professional services, and venture capital. It is conducive to the formation of economies of scale and the improvement of industrial competitiveness. At present, my country's biopharmaceutical industry has initially formed an industrial spatial pattern with the Yangtze River Delta and the Bohai Rim as the core, and the Pearl River Delta, Northeast China and other central and eastern regions developing rapidly.
The Made in China 2025 issued by the State Council lists biomedicine as one of the key areas to be vigorously promoted in the next step. Industry insiders predict that biomedicine and high-performance medical device-related companies are expected to usher in a historic development opportunity. With the support of policy, the biomedicine industry will usher in a golden period of development in the future, and various sub-industries are expected to benefit first. The industry predicts that by 2020, the scale of China's broad biomedicine market will reach 4 trillion yuan, the scale of the biomanufacturing market will reach 1 trillion yuan, the scale of the bio-agriculture market will reach 500 billion yuan, the scale of the bio-energy market will reach 300 billion yuan, and the scale of the bio-environmental protection market will reach 100 billion yuan. The total scale of the broad bio-industry market is about 6 trillion yuan, and the market prospects are extremely broad. In the future, China's biomedicine market is expected to become the world's second largest biomedicine market after the United States. China's biomedicine industry will become the next engine to promote social development after the information industry.
Share
Telephone
MOBILE PHONE
Company Address
No.68, Chengbei Road, Zhangcun Industrial Park, Jiangning District, Nanjing City
Main Products